# Artiva Biotherapeutics

异体 NK（AB-101） — 即用型脐血剂量.

Source: https://cn.bioecon.ru/companies/artiva-biotherapeutics/
Updated: 2026-06-24

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 自成立至2026年6月30日累计毛募集金额$741.9 million | https://www.stocktitan.net/sec-filings/ARTV/10-q-artiva-biotherapeutics-inc-quarterly-earnings-report-330c0f79d6d2.html |
| 产能 | 现有圣地亚哥设施的AlloNK产能足以每年治疗超过1,000名自身免疫疾病患者 | https://s203.q4cdn.com/960442723/files/doc_presentations/2026/Mar/10/Artiva-Corporate-Deck_March-2026.pdf, https://www.artivabio.com/nk-cell-technology/ |
| 生产基地 | 位于加州圣地亚哥的9,000平方英尺cGMP合规细胞生产中心 | https://www.artivabio.com/nk-cell-technology/, https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948ds1.htm |
| 监管批准 | AlloNK获FDA快速通道(Fast Track)资格,用于难治性类风湿关节炎 | https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx, https://www.artivabio.com/nk-cell-therapy-pipeline/, https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948ds1.htm |
| 员工人数 | 截至2026年3月31日为106名员工 | https://stockanalysis.com/stocks/artv/employees/ |
| 营收 | 截至2026年6月30日，无产品销售收入 | https://www.stocktitan.net/sec-filings/ARTV/10-q-artiva-biotherapeutics-inc-quarterly-earnings-report-330c0f79d6d2.html |

独立来源: investors.artivabio.com, s203.q4cdn.com, sec.gov, stockanalysis.com, stocktitan.net

## 技术

- [NK 细胞与 CAR-NK 疗法](https://cn.bioecon.ru/technology/nk-cell-car-nk-therapy/)